Silexion Therapeutics Corp SEC Filings

Silexion Therapeutics Corp filed an S-1 registration for an offering of ordinary shares, pre-funded warrants and ordinary warrants under Nasdaq tickers SLXN and SLXNW. The company is a development-stage RNAi therapeutics firm focused on KRAS-silencing candidates, including first-generation siG12D-LODER (Phase 1/2 data showing a numerical OS advantage in KRAS G12D/V patients) and second-generation SIL204 (preclinical stability, PK and in vivo efficacy data).

Financially, Silexion reported net losses of $16.5 million for 2024 (vs. $5.1 million in 2023) and had $3.5 million in cash as of June 30, 2025. Management states there is substantial doubt about the companys ability to continue as a going concern without additional financing. The S-1 discloses potential dilution from existing warrants, a $3.433 million promissory note convertible into shares, and an equity line (White Lion) that could issue up to $11.9 million of shares.

Silexion Therapeutics Corp (SLXN) filed an S-1 registering resale of up to 314,859 ordinary shares issuable upon exercise of warrants and discloses recent financings, operational results and liquidity constraints. For the six months ended June 30, 2025 the company reported a net loss of $4.238 million and cash and cash equivalents of $3.466 million. For the year ended December 31, 2024 net loss was $16.519 million, driven by higher R&D, G&A and financings costs. The company completed a public offering in January 2025 that generated approximately $5.0 million gross and subsequent warrant inducement transactions produced additional proceeds. Management notes substantial doubt about the company’s ability to continue as a going concern and disclosed Nasdaq listing compliance actions and two reverse share splits in 2024 and 2025.

Silexion Therapeutics Corp filed a Form S-8 to register up to 84,791 ordinary shares issuable under the Silexion Therapeutics Corp 2024 Equity Incentive Plan. The additional share allocation was approved by the board and by shareholders at the 2025 annual general meeting held July 14, 2025. The filing incorporates prior Form S-8 disclosures by reference and lists governing plan documents and legal and audit consents as exhibits.

Silexion Therapeutics reconvened a shareholder meeting on August 19, 2025 after an earlier adjournment for lack of quorum. At the reconvened meeting, holders of 1,459,924 ordinary shares (approximately 16.8% of issued and outstanding shares) were present in person or by proxy. Under the company’s Articles, after a half-hour lapse without a majority quorum, the shareholders present constituted a valid quorum to transact business.

The shareholders approved a proposal to increase the company’s authorized share capital from US$20,000 (divided into 1,481,482 ordinary shares) to US$121,500 (divided into 9,000,000 ordinary shares), with the par value remaining US$0.0135 per share. The filing lists vote totals as 699,871 (59.8%), 470,828 (40.2%), and 289,225, and states the proposal was approved by a simple majority of shareholders present. The amendment is attached as Exhibit 3.1.

Silexion Therapeutics Corp (SLXN) is a clinical-stage biotech developing SIL204, a second-generation siRNA targeting mutant KRAS in oncology. The company reported a net loss of $4.238 million for the six months ended June 30, 2025 and had $3.466 million of cash and cash equivalents on hand at that date. Operating cash outflow for the six months was $4.96 million and the accumulated deficit was $47.5 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern for 12 months without additional financing.

The company completed equity financings in January 2025 (gross proceeds ~$5.0 million) and inducement warrant exercises raising ~$3.276 million through June 30, 2025, and used an equity line of credit (ELOC) raising an aggregate of $3.1 million through June 30, 2025. Nasdaq trading and listing matters required two reverse share splits (1-for-9 and 1-for-15) and the company received a hearings panel decision allowing continued listing subject to a compliance plan to reach $2.5 million of shareholders equity by September 19, 2025.